Completed Trials

The effects of psilocybin on cognitive function in healthy participants

In partnership with COMPASS Pathways researchers from King’s College London have established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously.

The trial is now finished and results were published in The Journal of Psychopharmacology in March 2022. They represent an essential first step in demonstrating the safety and feasibility of psilocybin for use within controlled settings alongside talking therapy as a potential treatment for a range of mental health conditions.

Status	Completed, not recruiting
Participants	Adults
Clinical area	Healthy participants
Intervention	Psilocybin
Recruitment period	2018-2020
Funder	Compass Pathways
Sponsor	Compass Pathways

The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD) Study

King’s College London were part of a multi-centre trial led by COMPASS Pathways that is called P-TRD. The trial was conducted across 22 sites in 10 countries from Europe and the US. Adults with treatment resistant depression were given psilocybin at a dose of 25 mg, 10 mg, or 1 mg. The drug was administered together with psychological support and researchers measured changes in depression symptoms.

Status	Completed, not recruiting
Participants	Adults
Clinical area	Treatment resistant depression
Intervention	Psilocybin therapy
Recruitment period	2020-2021
Funder	Compass Pathways
Sponsor	Compass Pathways

An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3 [2 (dimethylamino)ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL PSILO) on Cognition in Patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) are debilitating and there are few treatment options. With funding from Beckley PsyTech researchers from King’s investigated the efficacy of psilocybin at three doses for treating these headache attacks, particularly looking at its impact on thought processes.

Status	Completed, not recruiting
Participants	Adults
Clinical area	SUNHA
Intervention	3 doses of psilocybin
Recruitment period	2022
Funder	Beckley PsyTech
Sponsor	Beckley PsyTech

A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5 Methoxy N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects

In partnership with Beckley PsyTech, King’s researchers evaluated the safety and tolerability of the psychedelic 5 Methoxy N,N-dimethyltryptamine (5-MeO-DMT) which is found in a variety of plant species and secreted by one species of toad. It was administered nasally to healthy participants at one dosage and researchers assessed the percentage of participants that experienced any unfavourable and unintended signs, alongside various measures to assess what is happening to the drug when it is taken.

Status	Completed, not recruiting
Participants	Adults
Clinical area	Healthy participants
Intervention	5-Methoxy-N,N-Dimethyltryptamine
Recruitment period	2021 – 2022
Funder	Beckley PsyTech
Sponsor	Beckley PsyTech

Publications:

https://journals.sagepub.com/doi/full/10.1177/02698811211064720

Dr Dave Isaacs

Research

Research

Psychoactive Trials Group

Research

Psychoactive Trials Group

Based in